Emicizumab reduces re-hospitalization for bleeding in acquired haemophilia A

Haemophilia. 2021 Jul;27(4):e585-e588. doi: 10.1111/hae.14335. Epub 2021 May 29.

Authors

Sheh-Li Chen¹, Patrick Ellsworth², Raj S Kasthuri², Stephan Moll², Alice D Ma², Nigel S Key²

Affiliations

¹ Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, North Carolina, USA.
² Department of Medicine, Division of Hematology and Blood Research Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

PMID: 34050698
DOI: 10.1111/hae.14335

No abstract available

Keywords: acquired hemophilia A; emicizumab.

Publication types

Letter

MeSH terms

Antibodies, Bispecific*
Antibodies, Monoclonal, Humanized / therapeutic use
Hemophilia A* / complications
Hemophilia A* / drug therapy
Hospitalization
Humans

Substances

Antibodies, Bispecific
Antibodies, Monoclonal, Humanized
emicizumab